Signet Laboratories, Inc. Announces Availability Of Two New Monoclonal Antibodies, L1 And PTEN
DEDHAM, Mass., June 13 /PRNewswire/ -- Signet Laboratories, Inc., a leading medical diagnostics/research company specializing in the development of monoclonal antibodies and diagnostic assays for cancer, infectious disease, and neurodegenerative disease, today announced the availability of two new monoclonal antibodies L1 clone 14.10 and PTEN clone 6H2.1